INTERVIEW: ADDF optimistic on Alzheimer's drugs despite recent setbacks
This article was originally published in Scrip
Executive Summary
Howard Fillit, executive director and chief scientific officer at the Alzheimer's Drug Discovery Foundation (ADDF) in New York, is optimistic about the Alzheimer's field despite multiple high-profile setbacks for late-stage therapeutics seeking to slow or stop progression of the disease.